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In a phase II study, 43 renal cell carcinoma patients were treated with individualised doses of ABR-214936; a fusion of a Fab
recognising the antigen 5T4, and Staphylococcal enterotoxin A. Drug was given intravenously on 4 consecutive days, treatment was
repeated 1 month later. Treatment was associated with moderate fever and nausea, but well tolerated. Of 40 evaluable patients, 28
had disease control at 2 months, and at 4 months, one patient showed partial response (PR) and 16 patients stable disease. Median
survival, with minimum follow-up of 26 months was 19.7 months with 13 patients alive to date. Stratification by the Motzer’s
prognostic criteria highlights prolonged survival compared to published expectation. Patients receiving higher drug exposure had
greater disease control and lived almost twice as long as expected, whereas the low-exposure patients survived as expected.
Sustained interleukin-2 (IL-2) production after a repeated injection appears to be a biomarker for clinical effect, as the induced-IL-2
level on the day 2 of treatment correlated with survival. The high degree of disease control and the prolonged survival suggest that
this treatment can be effective. These findings will be used in the trial design for the next generation of drug, with reduced antigenicity
and toxicity.
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Renal tumours account for approximately 200000 new cases
worldwide each year, roughly 3% of all cancers and the incidence is
increasing, though this is largely owing to improvements in
diagnosis. It often presents at an advanced stage with approxi-
mately 1/3 of cases already having established metastases leading
to high mortality rates (Quinn et al, 2001). Approximately, 1/3 of
patients with local disease are cured by surgery but as many as
40% will go on to develop metastases after surgery. Treatment
options for metastatic disease are limited, as the cancer tends to be
resistant to both chemotherapy and radiotherapy (Mulders et al,
1997). Instead, interferon-a (IFN-a) and interleukin-2 (IL-2) are
widely used for the treatment of metastatic renal cell carcinoma
(RCC). However, response rates are low (14–20%) with some
survival advantage demonstrated for IFN-a, but not for IL-2
(Collaborators, 1999; Yang et al, 2003). Thus, so far immunother-
apy has been the most useful therapeutic approach for RCC, but
recently antiangiogenic agents have shown encouraging data in
clinical trials (de Gramont and Van Cutsem, 2005; Rini et al, 2005;
Motzer et al, 2006).
Tumour-targeted superantigens (TTS) work by polyclonal
activation of the patients’ own T cells. Superantigens such as
Staphylococcal enterotoxin A (SEA) are secreted molecules
employed by pathogens to evade the immune system. Their
binding to major histocompatibility complex (MHC) class II
molecules on antigen presenting cells (APC) and T-cell receptors
of a subset of T cells-bearing particular Vb-chains (Dermime et al,
2004; Petersson et al, 2004) activates the T cells in an antigen-
independent manner. Activation leads to the expression of
perforin and the production of cytotoxic and proinflammatory
cytokines and thus death of the APC (Fischer et al, 1990; Dohlsten
et al, 1991b). Targeting of superantigens towards tumours induces
a strong, local cytotoxic T-cell attack, which directly kills tumour
cells and leads to inflammation and the local accumulation of
tumouricidal cytokines (Dohlsten et al, 1991a, 1994, 1995; Litton
et al, 1997,1999).
ABR-214936 is a recombinant fusion protein between a modified
form of SEA and a murine Fab that recognises the tumour-
associated antigen 5T4. In this, SEA has been engineered for
reduced MHC class II binding giving it a much improved safety
profile compared to fusions with wild-type SEA (Alpaugh et al,
1998a; Brodin et al, 1998; Forsberg et al, 2001; Cheng et al, 2004).
The 5T4 oncofoetal antigen is a transmembrane glycoprotein (Hole
and Stern, 1988, 1990). It is expressed by a wide range of cancers
(Southall et al, 1990), including gastric, colorectal, ovarian
(Dermime et al, 2004), non-small cell lung (NSCLC) (19) and at
high levels by 95% of RCC (Forsberg et al, 2001; Griffiths et al,
2005). Despite its widespread expression in malignancy, it shows
only limited expression in normal adult tissues (Southall
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set al,tvjmline 1990; Forsberg et al, 2001), making it an ideal target
for antibody-mediated therapy. Renal cell carcinoma is particu-
larly suitable for therapy with ABR-214936 as it is well vascularised
and a high proportion (495%) of tumours are positive for 5T4
expression.
In the phase I study of ABR-214936 in NSCLC, the maximum
tolerated dose (MTD) as a function of pre-existing anti-SEA
antibody was determined (Cheng et al, 2004). The reported major
side effects of ABR-214936 included pyrexia, hypotension, rigours,
nausea and lethargy. Here we report the further investigation of
ABR-214936 at the phase II level in RCC patients using a dose-
regimen based on the findings of the earlier study.
PATIENTS AND METHODS
Patient population
This open-label phase II study was conducted between December
2001 and March 2003 according to the protocol approved by the
Local Research Ethical Committees of both centres. All patients
gave informed written consent, were X18 years of age, of either
sex with greater than 80% Karnofsky’s rating and life expectancy
greater than 6 months. Adequate organ function was defined as
WBC p3.000mm
 3, absolute neutrophil count p1500mm
 3 or
platelets p100000mm
 3, haemoglobin o100gl
 1, bilirubin p2
times the upper normal limit and creatinine 1.5 times normal,
FEV1470 and SaO2490%. Patients with uncorrected hypercalcae-
mia, poorly controlled hypertension or taking b-blockers were
excluded, as were patients with cardiac arrhythmia or significant
cardiac disease, a history of cerebrovascular disease, seizures,
asthma or had an autoimmune disease. Patients who had
undergone major surgery within 3 weeks received chemo-, radio-
or immunotherapy, including immunosuppressive therapy or had
participated in another study within 4 weeks of treatment were
excluded. No patient with known seropositivity for HIV or
hepatitis B/C or with a known hypersensitivity to murine proteins
was included. Following recruitment and within 21 days of
commencing the treatment, each patient underwent a physical
examination including a 12-lead electrocardiogram and a full
medical history taken. The sample size was set as 45 evaluable
patients using a Fleming’s one sample, two-stage testing procedure
for phase II studies.
Study drug
ABR-214936 (5T4FabV13SEAD227A) is a 73kDa fusion protein
consisting of an engineered 5T4 Fab moiety genetically fused via
the C terminus of the heavy chain to SEAD227A, produced in
Escherichia coli (Forsberg et al, 2001). The drug compound was
manufactured at Pharmacia’s GMP pilot production facility in
Stockholm Sweden, formulated and packed at their facility in
Nerviano, Italy. It was shipped directly to the study centres on dry
ice with temperature being monitored.
Treatment plan
Patients were treated with four consecutive daily 3-h infusions of
ABR-214936 at an individualised dose; a second treatment cycle
was given 4–6 weeks later. Patients were given individualised
doses dependent on their anti-SEA antibody titre at baseline and
day 28 for treatment cycles 1 and 2 respectively, according to the
schedule in Table 1. To mitigate the hypotensive effects of
treatment, patients were hydrated with 1l of saline given over
2h before commencing the infusion; in addition, patients were
treated prophylactically for fever with acetaminophen. Dose
reduction was undertaken if the patient experienced multiple
drug-related adverse events (AEs) at the time of administration.
Thus, within the first cycle the second infusion was given at 75% of
the calculated dose and if symptoms continued further reduced to
50% for subsequent days. Treatment was halted and the patient
withdrawn from the study if the AE persisted at this lower dose.
Safety and efficacy evaluation
Patient vital signs were monitored at regular intervals throughout
treatment; blood samples taken before and after each infusion were
used to follow changes in blood chemistry, immune cell
populations, pharmacokinetics and the quantification of circulat-
ing cytokines as described previously (Giantonio et al, 1997).
Adverse events during the study were recorded using the NCI
common toxicity criteria version 2, which was current during the
period of the study.
Fab-specific human anti-mouse (HAMA) titres, at baseline and
following each cycle of treatment were determined by enzyme-
linked immunosorbent assay (ELISA) (Immunomedics, Warren,
NJ, USA). As a potential correlate for early-onset AEs systemic
levels of IL-2 were measured by ELISA (Diaclone, Besanc¸on,
France) 2h after cessation of infusion on the first 2 days of
treatment during the first cycle.
Following treatment, at days 56 and 112, previously identified
target lesions were assessed according to the standard response
evaluation criteria in solid tumours (RECIST). Patients exhibiting
reduction in tumour size at day 56 were rescanned on day 84 for
confirmation.
Survival analysis based on date of death or date known alive in
May 2005 was conducted with a minimum follow-up of 26 months.
The 43 treated patients were divided into two groups depending on
their individual drug exposure, that is, total dose received during
cycle 1 (ngkg
 1) divided by anti-SEA antibody titre (pmolml
 1);
those above the median value (15.3) were defined as the high-
exposure group (N¼22). Patients were also grouped according to
their ability to sustain a systemic IL-2 response to treatment; those
with IL-2 levels above the median (4.0ngml
 1) following the
second infusion of the first treatment cycle were defined as high
IL-2 responders (N¼21).
Each patient was classified as high, intermediate or low risk
using the methods described by Motzer (Motzer, 2003; Motzer
et al, 2004) for untreated or previously treated patients as
appropriate. Survival for a matched control group was extra-
polated from published survival curves. The percentiles of the
published curves were used as matched patients and the 43
patients were compared to a Kaplan–Meier curve of reference
patients with the same Motzer’s risk. The simulated patients were
not used in any statistical test.
The influence of exposure, risk, anti-SEA, IL-2, lactate
dehydrogenase (LDH), body weight, performance status and sex
were tested with Cox models in SAS (PROC PHREG, SAS Institute
Inc., Cary, NC, USA). A univariate analysis was performed to select
important covariates. Identified covariates were used in multi-
variate analyses to determine the treatment effect after adjusting
for risk factors.
RESULTS
Patient characteristics and treatment
A total of 43 Caucasian patients with a confirmed diagnosis of RCC
were treated. Of these, 35 were males and eight females; the mean
age was 57.6 (26–76) years; full details are outlined in Table 1. All
patients had metastatic disease distributed as lung (n¼29), lymph
node (n¼19), liver (n¼4) and other sites including bone and soft
tissues (n¼10). Thirty-four patients had undergone resection of
their primary tumour as initial treatment and a further five had
had palliative nephrectomy. Seven had palliative surgery to remove
metastases and one to relieve pressure on the spine. Thirty-one
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spatients had received previous systemic treatment; chemotherapy
and or immunotherapy, predominantly IFNs; of these, five patients
also received radiotherapy and three patients received only
radiotherapy. The median time between last previous systemic
therapy and treatment with ABR-214936 was 19 weeks (range 4–74
weeks). According to the prognostic categories defined by Motzer
et al (2004; Motzer, 2003), there were four high; 24 intermediate
and 15 low-risk patients.
A total of 40 patients received two treatment cycles, and were
evaluable for efficacy by computed tomography (CT) scan; of
these, five patients received three cycles and a single patient
received four cycles of treatment. For evaluation of survival, all 43
patients were included in the analysis.
Safety and immunological response
Haematology, biochemistry and urinalysis gave some results
outside the normal ranges, but none was considered clinically
significant. During the first cycle, circulating white blood cells in
particular, monocytes and lymphocytes were transiently reduced,
but these changes were less pronounced after the successive
infusions and not observed during the second cycle. There was a
daily transient increase in temperature of 0.5–11C, peaking at 8h
and lessening on each day. A drop in systolic and diastolic blood
pressure of 5–20mm Hg was seen during the infusions of cycle
one.
Generally, the drug was well tolerated; 30 patients experienced
treatment-related AEs during either cycle of treatment, the
majority of which were mild or moderate. During cycle 1, 14
patients experienced AEs that resulted in a dose reduction or
delay; these were typically either multiple grade 1 reactions or
grade 2 pyrexia combined with grade 2 hypotension. In two cases,
cessation of treatment occurred, both due to grade 3 hypotension.
Only one patient required dose reduction in cycle two due to
multiple grade 1 AEs. In all cases, the AEs were easily managed and
resolved within 24h of onset. The most frequent AEs experienced
in cycle 1 were pyrexia (22), rigour (13), lethargy or fatigue (14),
nausea or vomiting (14), hypotension (10) and hypertension
(three). During the second cycle, the frequency of AEs was reduced
compared to cycle 1, lethargy being the most common symptom,
occurring in nine patients. Most of the patients had increased
systemic IL-2 levels 5h after the start of the first and second
infusions of the first cycle.
Anti-SEA titres determined at each study visit (Table 2) were
similar to previous studies (Cheng et al, 2004). There was a 536-
fold increase in median titre following the first cycle but this was
not boosted by further drug exposure and generally declined after
the second cycle. Notably, four patients did not show increased
anti-SEA titres after the first therapy cycle. No patients had
measurable HAMA before commencing treatment (Table 2).
Following one cycle of treatment, nine of 41 patients (22%) had
a measurable HAMA titre above the limit of quantitation for the
assay (X0.24pmolml
 1). After the second cycle of treatment, this
had risen to 22 of 26 patients (85%).
Efficacy
Primary efficacy was evaluated using CT scan according to the
RECIST criteria. At day 56, one patient showed a partial response
(PR), whereas the largest proportion, 27 patients, showed stable
disease (SD) and 12 had progressed (PD). Three patients were not
evaluated as they had either withdrawn consent (N¼2) or not
Table 1 Patient characteristics, dosing and response to treatment
Characteristic No % Characteristic No %
Total 43 100 Male 35 81
Age, years Previous therapy
Median 57.6 — Median no of treatments 1 —
Range 26–76 — Range 0–4 —
Radiation 8 19
Karnofsky performance status (%) IL-2 13 30
100 8 19 IFN 25 58
90 28 65 Chemotherapy 8 19
80 7 16 None 9 21
Motzer risk factor Patients with metastatic disease 43 100
0¼low 15 35 Lung 29 67
1¼intermediate 24 56 Liver 4 9
¼high 4 9 Lymph nodes 19 44
Other (including bone) 10 23
Histology
Clear cell 27 63 Dosing with ABR-214936 (cycle 1)
Papillary 1 2 a-SEA titre pmolml
 1 Dose ngkg
 1
Ductal 2 5 o40 60 1 2
Unspecified 13 30 41–50 100 7 16
51–90 300 15 35
Drug exposure (Dose:a-SEA) 91–150 500 6 14
High (415) 22 51 151–300 800 9 21
Low (o15) 21 49 4301 1200 5 12
Previous surgery Best overall response (day 56)
Nephrectomy 34 86 PR 1 2
Removal of metastases 7 16 SD 27 63
None 6 14 PD 12 28
N/A 3 7
IL-2¼interleukin-2; IFN¼interferon; SD¼stable disease; PD¼progressed; PR¼partial response.
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sbeen able to undergo CT-scan (N¼1). At day 112, one patient
continued to show PR, 16 SD, 21 had progressive disease and two
further patients were nonevaluable.
The changes in size of target lesions at days 56 and 112, relative
to baseline measurements are illustrated in Figure 1. At both
assessment times, patients with high drug exposure exhibited a
slower rate of tumour growth or greater reduction in size than the
low-exposure group. At day 56, in addition to the one clear
response, a further nine patients showed a 10–25% reduction in
tumour volume. Of these, seven had high drug exposure compared
with only two low exposure patients. Similarly, at day 112 of the six
patients showing a reduction in tumour volume, four were in the
high and two in the low exposure groups. A 25% reduction in one
patient at day 56 was sustained at day 112.
Median time to progression was 4.0 months and median survival
was 19.7 months with 13 patients still alive at the time of writing, a
2-year survival of 42%. Figure 2A shows patient survival with a
minimum follow-up of 26 months plotted against a simulated
patient population with matching risk factors as defined by
Motzer’s score. In our patient group, the median survival of 19.7
months compares favourably with the expected survival of 13.7
months. Expected median survival for our patients in the high,
intermediate and low risk categories were 5.1, 11.3 and 21.8
months, respectively, by comparison, their observed survival was
3.1, 15.6 and 25.8. Both the low and intermediate risk patients
show an increase in survival time compared to published
expectation.
From a toxicity perspective, there was a correlation between
MTD and anti-SEA levels; thus for this product, drug exposure is
defined as dose divided by anti-SEA levels. Patients receiving
higher exposure show a survival advantage compared to the low
exposure group (Figure 2B); 26.6 months vs 12.1 months, and have
a greater proportion of long-term survivors (nine vs four).
Expected survival for the matched controls was 14.5 and 12.2
months, respectively.
Serum IL-2 was measured on days 1 and 2 of the first treatment
cycle (Table 2). Patients categorised as high-IL-2 responders on
day 2 (X4pgml
 1) have a better outcome than low responders
(Figure 2C). No correlation between day 1 IL-2 levels and survival
was observed. A univariate analysis indicated five significant
(Po0.05) factors associated with increased survival. Those were
favourable Motzer’s risks, normal LDH levels, high weight, high
exposure and high-IL-2 levels after the second infusion. A bivariate
analysis, correcting for Motzer’s risks, supported the univariate
analysis and both exposure and IL-2 after the second infusion
reduced the risk of dying by about 50%. Finally, a multivariate
analysis of IL-2 after the second infusion, exposure and Motzer’s
risks was a very good model (n¼43). In this, the risk of dying was
reduced by about 48% (95% CI: 20–66%) for each unit in the log
scale for IL-2 (1 unit increase in the e-logarithm corresponds to a
2.7 times higher value). The corresponding reduction in the risk of
dying for patients with high exposure compared to those with a
low exposure was 71% (95% CI: 31–88%). Analyses with the
covariate ‘Motzer’s risks’ replaced with ‘elevated LDH’ as well as
addition of body weight as covariate supported those findings.
Thus, drug exposure and sustained IL-2 levels after second
infusion act additively.
The connection between disease control, survival, exposure and
IL-2 response on day 2 in the first cycle is illustrated in Figure 2D.
The best disease control and survival was seen in the group having
both high exposure and high IL-2 and the poorest with low
exposure and low IL-2. However, both the high exposure/low IL-2
and low exposure/high IL-2 groups also show evidence of disease
control and improved survival. There is a correlation between
exposure and disease control at day 112, which affects the long-
term survival.
The patient who showed PR received an exposure during the
first cycle, five times greater than the median. This patient
experienced multiple grade 1 AEs in the first cycle, but later
received three further cycles at full dose. As can be seen in Figure 3
Table 2 Physiological responses to ABR-214936 treatment
Anti-SEA (pmolml
 1) HAMA (pmolml
 1) IL-2 (pgml
 1)
Visit n Median Range n Median Range Mean7s.d. Median Range
Baseline 43 87.0 15–6400 43 0 0–0
Day 1 43 37.8770 9.2 0–357.7
Day 2 43 6.7713.3 4 0–87.2
Day 28 40 46700 79–445000 41 0.058 0–9.36
Day 56 38 31600 113–241000
Day 112 27 25100 175–176000 26 1.542 0–16.4
Anti-SEA and HAMA titres measured at baseline and after each cycle of treatment and circulating IL-2 measured on days 1 and 2 of cycle 1.
0.25
0.5
0.75
1
1.25
0
012 12 –1 –2
S
u
m
 
t
a
r
g
e
t
 
l
e
s
i
o
n
s
 
(
d
a
y
 
5
6
/
b
a
s
e
l
i
n
e
)
Quantile
High exp
Low exp
0.25
0.5
0.75
1
1.25
0
0 –1 –2
S
u
m
 
t
a
r
g
e
t
 
l
e
s
i
o
n
s
 
(
d
a
y
 
1
1
2
/
b
a
s
e
l
i
n
e
)
Quantile
High exp
Low exp
20
19
13
12
Figure 1 Change in tumour volume at day 56 and day 112 relative to baseline, measured by CT scan. The rate of growth for the high drug exposure
group is slower than for the low exposure group. The number of patients in each group is indicated.
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sthere was a dramatic reduction of the metastatic lesions in the
liver, there was also shrinkage of a local recurrence. The patient
has survived for more than 36 months since treatment and no
longer has any evidence of active disease at any of the sites;
however, is classified as a PR based on the response at day 112. At
12-months follow-up (Figure 3C) there remained an indeterminate
CT shadow at one lesion site in the liver, but by 19 months this had
completely resolved and both sites remain clear at 36 months
(Figure 3D). Although, spontaneous regression is known in RCC, it is
relatively rare and there is no reliable predictor for when this is likely
to occur. In our experience the median duration of spontaneous
remission is approximately 7 months; consequently the long-term
disease-free survival of this patient is strong evidence for drug-
induced remission. A second patient, with both liver and skin
metastases, classified as PD owing to progression of the skin
metastasis, showed complete resolution of the liver metastasis after
treatment and following the surgical removal of the skin metastasis, is
considered to be in complete remission. Interestingly, these two
patients showing the best clinical outcome also had the highest IL-2
responses on day 2 of treatment (17.8 and 87.2pmolml
 1).
Four patients were evaluated by 18-fluorodeoxyglucose -positron
emission tomography (FDG-PET) at day 56, all showed SD
by CT at day 112; however, one showed a response using PET, but
only marginal shrinkage using CT scan. Two patients were
confirmed as SD and one showed progression.
DISCUSSION
In this paper, we present the first data from RCC patients treated
with a tumour-targeted superantigen. Despite limited patient
numbers and no randomized control group, the prolonged survival
suggests treatment benefit, based on two-independent compar-
isons. First, our patients had a median survival of 19.7 months,
considerably longer than the 13.7 months survival (Figure 2A) in
matched controls predicted from the extensive analyses by Motzer
(2003; Motzer et al, 2004). It is also longer than the 8–15 months
survival seen with other therapeutic agents assessed in recent
studies in similar patient populations (Mekhail et al, 2005). These
studies have included immunotherapy with IFN-a or IL-2 alone or
in combination with established chemotherapy (Motzer and Russo,
2000); thalidomide (Clark et al, 2004), 5-FU (O’Brien et al, 2004;
Rathmell et al, 2004), chemotherapy; gemcitabineþoxaplatin
(Porta et al, 2004), gemcitabineþcapecitabine (Waters et al,
2004) and experimental agents such as Gefitinib (Dawson et al,
2004).
Second there is a relationship, although not significant
(P¼0.098), between drug exposure and a reduction in the rate
of tumour growth (Figure 1). Furthermore, a relationship exists
between drug exposure and survival (Figure 2B), where high
exposure patients lived twice as long as low exposure patients. To
simulate the expected survival times of matched controls we used
prognostic factors described previously (Motzer, 2003; Motzer
et al, 2004) to group them according to risk and whether they had
PD on previous therapy (i.e. IFN-a).
Despite the long survival times, the response rate was rather
modest. However, a large fraction of the patients had SD lasting for
at least 4 months, which is comparable or better than concurrent
studies in similar patients with other experimental agents (Dawson
et al, 2004; Porta et al, 2004; Rathmell et al, 2004). Patients who
received a high exposure were more likely to have disease control
at day 112 and a long survival (Figure 2D). It is clear that several
novel anticancer therapies give clinically beneficial effects without
giving objective responses on CT scan; however, FDG-PET analysis
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Figure 2 Survival for the patients treated with ABR-214936 was compared to a matched simulated control population with equivalent Motzer’s
characteristics. Overall, median survival (A) was 19.7 months vs 13.7 for the controls and 2-year survival was 42 vs 27%. As a function of drug exposure (B),
median survival for the high-exposure group was 26.6 vs 12.1 months for the low exposure group (controls 14.5 and 12.2 months). As a function of IL-2
after the second infusion (C), median survival for the high exposure group was 25.2 vs 10.2 months (controls 14.0 and 13.3 months). Comparing drug
exposure, disease control and IL-2 response to survival (D) shows that patients with high IL-2 after the second infusion and high exposure are more likely to
have disease control at day 112 and the longest survival. The number of patients in each group is indicated.
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smay be a useful tool to gain further information. Of four patients
who showed SD by CT, one showed a response using PET but the
shrinkage using CT scan was only 13%. This patient from the
intermediate risk group is still alive after more than 30 months.
Another patient showed progression using PET but only a 5%
tumour increase using CT scan. This patient in the high-risk group
lived 9 months. Thus, PET may be a better tool than CT for the
evaluation of tumour responses following ABR-214936 therapy.
Interestingly, two patients with liver metastases, associated with
poor prognosis in RCC (Mekhail et al, 2005), showed complete
eradication of these metastases after ABR-214936 treatment. In a
previous trial using another antibody targeted superantigen,
eradication of liver metastases was also observed (Alpaugh et al,
1998a) and it is therefore possible that the liver associated disease
is particularly sensitive to superantigen therapy.
The mechanism of action of the TTS involves targeting of
cytotoxic-T cells to the tumour tissue. However, on the basis of
preclinical observations (Rosendahl et al, 1996; Litton et al, 1997)
this is achieved by a stepwise process. Initially, the systemic
activation and expansion of the superantigen reactive T cells, then
localisation of the activated T cells to the tumour followed by T
cell-mediated killing of the tumour cells. This multistep process
necessitates the repeated administration of the fusion protein.
In previous studies (Alpaugh et al, 1998b; Cheng et al, 2004), the
occurrence of high-systemic levels of IL-2 correlated with toxicity.
In the present study, post-infusion IL-2 levels were measured on
the first 2 days of treatment as this coincided with the majority
of AEs. This analysis showed that 68 of the 74 rapid-onset AEs
occurred in the group of patients with IL-2 above the median on
day 1 of treatment (49.2pgml
 1), confirming the previously
observed correlation. However, in this study we have been able to
go further in the understanding of the relationship between
systemic IL-2 and the mechanism of action of TTS therapy by
describing a direct relationship between a patient’s ability to
sustain an IL-2 response following the second infusion of ABR-
214936 and improved survival. Patients mounting a sustained IL-2
response had a median survival more than twice that of
nonresponders (Figure 2C). This difference was not a result of
covariation with performance status or Motzer’s risks (data not
shown). Furthermore, the IL-2 levels seen were lower than those
achieved during systemic IL-2 therapy, ruling out that the survival
benefits were primarily caused by the IL-2. Notably, there was no
correlation between the IL-2 levels induced after the first infusion
and survival, indicating that it is the sustained T-cell activation
that is necessary for therapy as suggested by preclinical findings
(Rosendahl et al, 1996).
A phase I trial of ABR-214936 performed in patients with NSCLC
(Cheng et al, 2004) had the primary end point of safety, but CT
scan and survival were also investigated. Interestingly, several of
the observations in our phase II study were seen in the phase I
trial. For instance, despite no objective responses being recorded, a
large proportion of the patients showed SD (Cheng et al, 2004).
Also, there was a correlation between high exposure and longer
survival (unpublished observation).
The rate of induction of HAMA observed in this study following
one and two treatment cycles was 22 and 85%, respectively
(X0.24pmolml
 1), comparable to the frequency reported for
other antibodies used in treatment or imaging of solid tumours
(Mirick et al, 2004). However, the magnitude of this reaction is
significantly lower than those reported previously, by a factor of
between 9.5 and 265 times depending on the type of assay used
(Kricka et al, 1993; Mirick et al, 2004). Thus, the induction of a
HAMA is unlikely to have any significant contribution to the
biodistribution or toxicity of the ABR-214936 when compared to
the level of pre-existing anti-SEA seen in most patients (Table 2).
The side effects recorded in this phase II trial were generally
mild and easily managed. In most cases they involved fever, nausea
and rigours. This is similar to the side effects observed in the phase
I trial which suggest that the product has a similar toxicological
profile in RCC and NSCLC patients. However, even though the side
AB
C D
Figure 3 CT scans of the patient who showed sustained PR during the trial: At baseline (A), day 84 (B), 12 (C) and 36 (D) months post-treatment.
Resolution of one liver metastasis is evident by day 84 with significant ablation of the second, which also eventually resolves. The patient is a long-term
survivor at þþ36 months and considered in full remission.
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seffects were mild, there is a correlation between MTD and the
patients’ anti-superantigen antibody titre. Patients with relatively
higher antibody titres tolerated higher doses of ABR-214936 with
identical side effect profile as compared to patients with lower titres
receiving lower doses. Patients were grouped according to their
anti-SEA titres; doses received varied between 60ngkg
 1day
 1 for
the lowest titre group and 1200ng
 1kg
 1day
 1for the highest. From a
safety point of view, this appears to have been a good approach,
but a consequence was that the patients received different
exposures (ratio of administrated dose of ABR-214936 divided
by anti-SEA). As there was a strong survival benefit for patients
receiving a higher ratio, this dose group strategy has to be
modified to make sure that all future patients are optimally dosed.
Toxicity during the second cycle was considerably lower than
during the first and only one patient required dose reduction. This
is because, relative to the first cycle, most patients may have been
under-dosed owing to their increased anti-SEA titre.
Although it is possible to measure the patients’ titres of anti-SEA
antibodies before therapy, it is not a convenient approach.
Therefore, in parallel to the clinical trials of ABR-214936, novel
superantigen variants with low reactivity to human anti-SEA
antibodies have been designed (Erlandsson et al, 2003). The
removal of the link between anti-SEA titre and dose should allow
every patient to receive an optimal dose and thus improve the
efficacy of treatment. One of those superantigen variants, SEA/
E-120 fused with the 5T4Fab moiety is the optimised TTS ABR-
217620 currently in phase I dose escalation studies in patients with
NSCLC, RCC and pancreatic cancers.
One future direction for the development of RCC therapy
currently under investigation is targeted antiangiogenic agents (de
Gramont and Van Cutsem, 2005; Patel et al, 2006). This includes
receptor tyrosine kinase inhibitors and antibodies directed against
growth factors such as vascular endothelial growth factor, either
singly or in combination. So far, the best objective responses have
been seen with sunitnib (40%) and combination therapy of
bevacizumab and erlotinib (25%) with median disease-free periods
of 8.7 and 11.1 months, respectively. The 2-year survival with
sunitinib is 40%, which is comparable to the 42% 2-year survival
for patients treated with ABR-214936 in this study (Motzer et al,
2006; Patel et al, 2006). However, the majority of patients still
progress following these antiangiogenic therapies; thus, although it
is an improvement on the response rate achieved with IFN-a or
IL-2 there is still a requirement for further development of novel
therapies.
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